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CD103 spurs on suppressors
 
An integrin expressed by gut dendritic
cells (DCs) gives regulatory T (T reg)
cells the green light for suppression,
according to a study on page 1051.
Annacker and colleagues show that DCs
expressing the integrin CD103 are re-
quired for T reg cells to subdue gut-
attacking effector T cells in a mouse model
of inflammatory bowel disease (IBD).
Naturally occurring T reg cells help
protect against autoimmunity and exces-
IBD in mice (right) is suppressed by T reg 
cells only if dendritic cells express CD103.
 
which is released from vagus nerve endings upon stimulation. 
Acetylcholine binds to nicotinic receptors on macrophages, thus 
inhibiting the synthesis and release of inflammatory cytokines 
such as TNF and interleukin (IL)-6.
Luyer et al. now show that the antiinflammatory effect of fat 
consumption in the rat model of hemorrhagic shock requires both 
CCK and the vagus nerve, as blocking CCK or severing the vagus 
nerve abolished this effect. With the vagus nerve intact, fat-
induced CCK inhibited the production of circulating TNF and IL-6 
and reduced gut permeability. Blocking nicotinic receptors also 
eliminated the antiinflammatory effects of dietary fat, thus 
solidifying the connection between fat-induced CCK and the cholinergic antiinflammatory pathway.
The authors think that this pathway might be important in suppressing gut inflammation in response to food proteins 
and normal gut bacteria, which immune cells might otherwise regard as foreign invaders. They also suggest that this 
pathway could potentially be targeted in patients as a way to reduce inflammatory complications after surgery. 
 
Fat ﬁghts inﬂammation
Dietary fat triggers the cholinergic antiinflammatory pathway via 
the vagus nerve.
 
A study on page 1023 reveals a potential benefit of much-maligned high fat foods. 
According to Luyer and colleagues, the same hormone that makes you feel full 
after a fatty meal might also prevent immune cells from mistakenly attacking 
food proteins as if they were foreign invaders.
Eating—particularly eating fat-rich foods—triggers the production of a 
hormone called cholecystokinin (CCK) by cells that line the small intestine. CCK 
binds to its receptor on cells in the gut, pancreas, and central nervous system (CNS), 
thus stimulating digestive functions, including gut peristalsis and insulin release, and 
triggering satiation. Luyer and his colleagues recently showed that dietary fat also 
blunts the inflammatory response in a rat model of hemorrhagic shock.
The new study connects CCK to a recently identified antiinflammatory pathway 
that is controlled by the vagus nerve. This pathway—dubbed the cholinergic 
antiinflammatory pathway—is mediated by the neurotransmitter acetylcholine, 
 
sive inflammation by suppressing the
activity of effector T cells. This group
had previously shown that transferring T
reg cells protects against T cell–induced
IBD in mice. The suppression of IBD
requires the cytokine TGF-
 
 
 
 and possibly
the high levels of CD103 that are seen
in a subset of T reg cells.
Annacker et al. now show, however,
that CD103 is not required on the effector
T cells for them to induce disease, nor on
the T reg cells for them to suppress dis-
ease. However, CD103 was not com-
pletely expendable. T reg cells could not
suppress colitis when transferred into
CD103-deficient mice, suggesting that
CD103 expression on non–T cells some-
how spurs the T reg cells into action.
The relevant CD103-expressing cells
were DCs, consistent with the study by
Johansson-Lindbom et al. (page 1063)
showing that CD103 marks lymph node
DCs that originated in the gut. But how
these DCs communicate with T reg cells
is not clear. Both groups showed that
CD103
 
 
 
 DCs, but not CD103
 
 
 
 DCs,
induced the expression of the gut-homing
chemokine receptor CCR9 on effector T
cells in vitro. This suggests that CD103
 
 
 
DCs might similarly induce CCR9
expression on T reg cells, thus endowing
them with the ability to migrate to the
gut—a possibility not yet tested in vivo.
But the effect of CD103 could also
be indirect, suggests senior author Fiona
Powrie. CD103 may help trap DCs in
the gut by binding to its receptor
(E-cadherin) on intestinal epithelial cells,
consistent with the recent finding that
CD103 is needed to retain pathogenic
CD8
 
 
 
 T cells in the gut during graft
versus host disease. Although this mech-
anism remains speculative, retention of
DCs in the gut might be a prerequisite
for endowing T reg cells with the ability
to suppress. 
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FoxP3 gets a new gig
 
On  page 1141, the one-trick transcription
factor FoxP3 reveals a new function. According
to Chang and colleagues, FoxP3 does more
than just drive regulatory T (T reg) cell devel-
opment; it also promotes the proliferation of
developing thymocytes.
FoxP3 is required for the development of
CD4
 
 
 
CD25
 
 
 
 T reg cells, which subdue the
activation of conventional T cells and thus
protect against chronic inflammation and auto-
immunity. Mice and humans that lack FoxP3
develop a spontaneous, multi-organ autoimmune
disease that has been primarily attributed to the
lack of T reg cells. But one fact suggests that
this explanation may be too simple. Irradiated
mice that are reconstituted with FoxP3-defi-
cient bone marrow do not develop disease,
suggesting that FoxP3 also functions in non-
hematopoietic cells.
Chang and colleagues now show that
FoxP3 is not exclusive to T cells, but is also ex-
pressed in thymic epithelial cells. In mice lack-
ing FoxP3, developing thymocytes were
unable to proliferate normally, resulting in thy-
mic atrophy. The proliferation defect was
caused by a lack of FoxP3 in thymic stromal
cells, rather than in T cells, as normal thy-
mocytes also failed to proliferate in a FoxP3-
deficient thymic environment.
How FoxP3 expression on thymic epithelial
cells helps drive thymocyte proliferation is
unknown. Also unclear is how the proliferation
defect contributes to autoimmune disease,
although there is a long-standing but poorly
understood link between thymic atrophy and
T cell–driven autoimmune disease. 
FoxP3 (red) is expressed on cortical epithelial cells 
(green) and drives thymocyte proliferation.
 
New target for T regs
 
The natural killer (NK) cell is a new target for regulatory T (T reg) cell
tyranny, according to a study on page 1075. Ghiringhelli and colleagues
show that the antitumor activity of NK cells is snuffed out by T reg cells,
allowing tumors to grow unchecked.
NK cells are innate immune cells that help destroy NK cell–sensitive
tumors, such as melanomas and gastrointestinal tumors, which express
activating ligands for these cells. The activation and antitumor functions
of NK cells are triggered by the binding of these ligands to the activating
receptor NKG2D on the NK cells. In many cancer patients, NK cell
activity is hampered by the shedding of NKG2D ligands from tumor cells
or by other unknown mechanisms.
This group recently showed that a drug that activates NK cells in
patients with gastrointestinal cancer improved their prognoses. They now
report that the patients who did not respond to this therapy had increased
numbers of circulating T reg cells, whereas the patients who responded
did not. The T reg cells from nonresponding patients prevented NK cells
from killing tumor cells in vitro.
In mice, transfer of T reg cells blocked the killing capacity of NK cells.
This inhibition depended on the expression of membrane-bound TGF-
 
 
 
on the T reg cells, which triggered the down-regulation of NKG2D on
the NK cells. Thus TGF-
 
 
 
–induced inhibition of NK cell activation,
which normally helps curtail inflammation and prevent autoimmunity,
helps certain tumors avoid being recognized by these killer cells. 
 
CCR5 saves lives
 
Although West Nile virus (WNV) infections 
have made headlines in recent years, little 
is known about how the virus causes 
disease or how the immune system fights 
back. On page 1087, Glass and colleagues 
show that immune cells must invade the 
central nervous system to combat the virus, 
and the chemokine receptor CCR5 is their 
entry ticket into the brain.
CCR5  mononuclear cells (black) 
infiltrate the brain and help elimi-
nate WNV infection.
 
WNV is an RNA virus that attacks the brain and can cause meningitis 
and encephalitis. Although infections with WNV can be fatal, most cases 
are mild or asymptomatic, suggesting that the immune system is capable 
of fighting off the virus. But the details of the anti-WNV immune response 
remain poorly characterized.
Glass and colleagues now show that WNV infection in mice triggers an 
influx of T cells, natural killer cells and macrophages into the brain in response 
to local production of chemokines. The influx of cells, which protected the 
mice against lethal infection, largely depended on the expression of CCR5 on 
the responding cells. In CCR5-deficient mice, fewer cells gained access to the 
brain and the infection was uniformly fatal.
To determine whether CCR5 is equally important for combating WNV 
infection in humans, the authors are now testing whether people who had 
severe or fatal infections with WNV were more likely to carry the CCR5 
deletion mutation. This mutation is best known for its ability to protect 
against HIV infection, as CCR5 is a cellular coreceptor for HIV. 
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